Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
Open Access
- 29 January 2021
- Vol. 8 (2), 91
- https://doi.org/10.3390/children8020091
Abstract
Extravasation can present serious accidental complication of intravenous drug application. While monoclonal antibodies do not show the necrotic potential of cytotoxic chemotherapy drugs, considerable inflammatory toxicity can occur, necessitating standardized operating procedures for the management of their extravasation. Here, we report the clinical course and management of dinutuximab beta extravasation in a 3-year-old child. Dinutuximab beta is a chimeric monoclonal antibody targeting the GD2 disialoganglioside on the surface of neuroblastoma cells that has in recent years gained significant importance in the treatment of high-risk neuroblastoma, now contributing to both first- and second-line therapy protocols. The dinutuximab beta extravasation reported here occurred when the patient received the antibody cycle as a continuous infusion over a 10-day period after haploidentical stem cell transplantation for relapsed high-risk neuroblastoma. The extravasated dinutuximab beta caused local pain, swelling, and hyperemia accompanied by fever and an overall deterioration in the general condition. Laboratory diagnostics demonstrated an increase in C-reactive protein level and total white blood cell count. Clinical complication management consisted of intravenous fluid therapy, local dabbing with dimethyl sulfoxide (DMSO), analgesia with dipyrone, as well as application of intravenous antibiotics to prevent bacterial superinfection in the severely immunocompromised host. The patient considerably improved after six days with this treatment regimen and fully recovered by day 20.This publication has 14 references indexed in Scilit:
- Monoclonal antibody extravasations: Two case reports and literature reviewJournal of Oncology Pharmacy Practice, 2020
- Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology GroupJournal of Clinical Oncology, 2020
- Current management of neuroblastoma and future directionCritical Reviews in Oncology/Hematology, 2019
- Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapyBiologics: Targets and Therapy, 2018
- Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trialThe Lancet Oncology, 2017
- Extravasation emergencies: state-of-the-art management and progress in clinical researchmemo - Magazine of European Medical Oncology, 2016
- NeuroblastomaNature Reviews Disease Primers, 2016
- Overview, prevention and management of chemotherapy extravasationWorld Journal of Clinical Oncology, 2016
- Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma.Journal of Clinical Oncology, 2015
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaThe New England Journal of Medicine, 2010